Most remote patient monitoring vendor comparisons start with price and stop there. But the vendors that end up causing the most trouble for a practice rarely fail on price — they fail on regulatory status, connectivity reliability, or missing compliance paperwork that only surfaces after a device is already in a patient’s home. For a practice sitting down to compare remote patient monitoring vendors, the evaluation should run through three specific filters before a contract ever gets signed: FDA status, connectivity architecture, and documented data-security compliance.
Start With Regulatory Status, Not Marketing Claims
Every device in an RPM kit — blood pressure cuffs, glucose meters, pulse oximeters, connected scales — is a regulated medical device, even though the RPM care model itself is not something the FDA approves as a single package. Most of these fall into Class II and go through the FDA’s 510(k) clearance pathway, meaning the agency compared the device to an already-marketed device and found it substantially equivalent. That is different from FDA approval, which is reserved for Class III devices carrying a higher risk profile, such as implanted or life-sustaining devices, and requires the more rigorous Premarket Approval process.
This distinction is not academic. Vendor sales materials routinely say "FDA-approved" when the accurate term for a blood pressure cuff or pulse oximeter is "FDA-cleared." A practice comparing vendors should ask each one for the specific 510(k) clearance number for every device in the kit and independently verify it rather than taking the claim at face value. This matters beyond correctness: for RPM services to be reimbursable by Medicare and most private payers, the physiologic monitoring devices used generally have to qualify as FDA medical devices, typically with 510(k) clearance in hand. A device without a verifiable clearance is a reimbursement risk, not just a labeling nitpick.
One more wrinkle worth asking about directly: some RPM software platforms are exempt from separate device regulation because they only display readings and surface alerts for a clinician to review, rather than independently diagnosing a condition or issuing autonomous treatment recommendations. If a vendor’s software crosses into automated clinical decision-making, that shifts its regulatory category, and a practice should understand which side of that line the platform sits on before relying on it.
Cellular or Bluetooth: The Connectivity Decision That Drives Adherence
Connectivity architecture is a bigger driver of program success than most feature checklists suggest, because it determines how many things can go wrong between a patient taking a reading and a clinician seeing it.
| Connectivity type | How it works | Practical trade-off |
|---|---|---|
| Cellular | Device transmits readings directly over a cellular connection, no paired phone or home internet required | Fewer points of failure and more consistent data flow; works "out of the box" for patients who are not comfortable pairing devices, at the cost of ongoing cellular connectivity built into the device |
| Bluetooth | Device pairs with a smartphone, tablet, or gateway hub that relays data over the patient’s own internet connection | Depends on the patient maintaining a working pairing and a stable internet connection; syncing or pairing failures translate into missed readings and extra staff time chasing down gaps |
Neither architecture is universally correct — a cellular device solves the tech-literacy problem for an older or less tech-savvy patient population, while Bluetooth can be perfectly workable where patients already have reliable connected devices. What a practice should press vendors on during evaluation is what actually happens when a connection drops: does the device queue and retransmit readings, does staff get notified of a gap automatically, and how much of the troubleshooting burden lands on clinical staff versus the vendor’s support line. Ask for the vendor’s real missed-reading rate across their existing client base, not just the theoretical uptime figure in the sales deck.
The Compliance Paperwork That Has to Exist Before You Sign
An RPM device continuously collects protected health information — vitals, timestamps, sometimes location — and transmits it off-site. That makes every RPM vendor a business associate under HIPAA, and a signed Business Associate Agreement is not optional; it is the baseline document that has to exist before any patient data flows through the vendor’s system. A vendor unable to produce a BAA on request is disqualifying on its own, regardless of how strong the hardware looks.
Past the BAA, the technical and administrative safeguards worth asking about directly include:
- Encryption in transit and at rest — readings should be encrypted from the moment they leave the device through storage on the vendor’s servers, not just during transmission.
- Role-based access controls and audit trails — the platform should log who viewed or exported a given patient’s data, and restrict access by staff role.
- Multi-factor authentication for any staff or clinician login that can reach patient monitoring data.
- Documented risk assessments — ask when the vendor last ran a security risk assessment on its own platform, and whether the practice can see a summary of the result.
- Independent security attestation — a SOC 2 report has become a common way for RPM vendors to demonstrate their controls were evaluated by an outside party rather than self-certified, and is a reasonable document to request during due diligence.
How the vendor’s platform hands data off to a practice’s own systems — and how cleanly that integration works day to day — is its own evaluation topic; the point at the vendor-selection stage is simply confirming the vendor supports a real integration path rather than manual data entry, and treating a "yes" on that question as one more item the compliance and technical due diligence needs to substantiate, not take on faith.
A Short Checklist Before the Contract Gets Signed
- Get the 510(k) clearance number for every physical device in the kit and verify it independently rather than trusting the word "approved" in a brochure.
- Confirm the devices meet the FDA medical-device status payers require for RPM reimbursement, in writing.
- Decide whether cellular or Bluetooth connectivity fits the practice’s actual patient population, and ask for real-world missed-reading rates, not uptime marketing numbers.
- Request the signed Business Associate Agreement template before any pilot patient data touches the platform.
- Ask for evidence of encryption, access controls, and a recent security risk assessment or SOC 2 report.
- Confirm the vendor supports a real data hand-off path into the practice’s existing systems, not a manual export-and-upload workaround.
Conclusion
Choosing among remote patient monitoring vendors comes down to verifying three things a glossy product sheet tends to gloss over: whether the devices actually carry the FDA clearance a vendor claims, whether the connectivity model fits the patients who will actually use it, and whether the compliance paperwork a practice is legally required to have is sitting in a drawer somewhere, signed, before the first reading ever gets transmitted. A practice that runs every finalist vendor through those three filters, rather than a feature list alone, ends up with a program that survives contact with real patients — and real audits.